Biomarker of Lung Disease in African Americans

非裔美国人肺部疾病的生物标志物

基本信息

批准号：
9980976
负责人：
RUSSELL Paul BOWLER
金额：
$ 79.31万
依托单位：
NATIONAL JEWISH HEALTH
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-08-15 至 2022-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9980976
关键词：
Address Admixture Advanced Glycosylation End Products African African American Asians Biological Markers Blood Cause of Death Chronic Obstructive Airway Disease Clinical Clinical Trials Collaborations Data Diagnostic tests Disease Disease Pathway Disease Progression Distal Early treatment European FDA approved Fibrinogen Functional Imaging Funding Gene Proteins Genetic Genomics Goals Knowledge Latino Lead Longitudinal cohort Lung Lung diseases Messenger RNA MicroRNAs Minority Molecular Molecular Profiling National Heart, Lung, and Blood Institute Not Hispanic or Latino Participant Pathogenesis Pathway interactions Patients Phenotype Plasma Population Population Attributable Risks Precision Health Prevention Proteins Proteomics Publications Pulmonary Emphysema Research Personnel Respiratory physiology Risk Risk Factors Severities Severity of illness Smoker Smoking Testing United States United States National Institutes of Health Whole Blood airway obstruction base biobank chronic airflow obstruction cohort cost disease phenotype disorder risk genetic variant genome sequencing health disparity high risk improved molecular subtypes novel novel diagnostics novel marker outcome forecast precision medicine progression marker protein expression protein protein interaction proteomic signature racial difference receptor smoking-related lung disease transcriptome sequencing transcriptomics treatment strategy virtual whole genome

项目摘要

PROJECT SUMMARY/ABSTRACT Chronic obstructive pulmonary disease (COPD) is the 3rd leading cause of death in the US1,2. Although COPD occurs predominantly in smokers, it is unknown why only a minority of smokers (~20-40%) develops chronic airflow limitation or destruction of distal airspaces (emphysema). Identification molecular profiles from current or former smokers who are likely to progress is a crucial step in understanding the pathogenesis of COPD and emphysema. There are very few publications that describe COPD biomarkers in large, well phenotyped cohorts that include a significant number of African Americans. This study will leverage large NIH- supported cohorts (COPDGene, SPIROMICS, and MESA-Lung) that have large number of well-characterized African Americans subjects with or at risk for COPD. Since the subjects have stored plasma and have been followed for 7-10 years with extensive clinical, physiologic, and imaging, we can very cost-effectively apply a proteomic approach. Furthermore, because the cohorts have other valuable Omics data, we can integrate the proteomic findings with whole genome sequencing and other advanced molecular studies such as genomics. This knowledge may help develop novel diagnostic tests and therapies for early prevention and treatment of COPD and will identify any markers that are specific to smoking-related lung disease in African Americans.

项目概要/摘要慢性阻塞性肺疾病 (COPD) 是美国第三大死亡原因1,2。虽然 COPD 主要发生在吸烟者身上，目前尚不清楚为什么只有少数吸烟者 (~20-40%) 会出现这种情况慢性气流受限或远端气腔破坏（肺气肿）。鉴定分子谱可能进展的当前或以前吸烟者是了解吸烟发病机制的关键一步慢性阻塞性肺病和肺气肿。很少有出版物大规模地描述 COPD 生物标志物表型群体包括大量非裔美国人。这项研究将利用大型 NIH- 支持的队列（COPDGene、SPIROMICS 和 MESA-Lung）拥有大量特征明确的患有慢性阻塞性肺病或有患慢性阻塞性肺病风险的非裔美国人受试者。由于受试者已储存血浆并已通过广泛的临床、生理和影像学随访 7-10 年，我们可以非常经济高效地应用蛋白质组学方法。此外，由于队列有其他有价值的组学数据，我们可以整合全基因组测序和其他高级分子研究（例如基因组学）的蛋白质组学发现。这些知识可能有助于开发新的诊断测试和疗法，以早期预防和治疗慢性阻塞性肺病 (COPD) 并将识别非裔美国人中与吸烟相关的肺部疾病特有的任何标志物。